FCRx are peripheral blood-derived bioengineered hematopoietic stem cells that were treated for removal of mature graft versus host disease (GVHD)-producing and antigen-presenting cells and enriched for facilitating cells (FC). Half of the FCs are CD11c+ and CD3ε− and half are CD11c- and CD3ε+.